PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: M&A
Genzyme Snubs Sanofi Offer
Less than 24 hours after offering to purchase Genzyme for $18.5 billion, Sanofi-Aventis was sent a letter of rejection from the biotech firm’s board of directors stating that the offer just wasn’t worth it.
“Without exception, each member of the Genzyme board believes this is not the right time to sell the company, because your opportunistic [...]
M&A Round-up • 3/25/2009
The latest round of merger and acquisition activities courtesy of our friends at Pharm Exec Europe:
• Just days after its purchase of Genentech, Roche has made another acquisition, albeit a much smaller one, of the German firm Innovatis. Roche will pay EUR 15 million for the cell analytics company.
• Oxford Gene Technology (OGT) is to [...]
Posted in Deals Also tagged ACM-Pivotal, Covance, Deals, Innovatis, mergers, Oxford Gene Technology, Pharm Exec Europe, Roche, Sense Proteomic, Swiss Pharma Contract Leave a comment
Roche and Genentech Seal the Deal
for $46.8 Billion
After months and months of back and forth over the true value of Genentech, Roche finally got the good news it’s been looking for: Genentech’s board of directors, this morning, approved Roche’s latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant.
Roche plans to keep the Genentech site in [...]
Conversation with Eisai’s Lonnel Coats
“The phones are ringing,†said Lonnel Coats, president of Eisai and a plenary speaker here at HBA’s Leadership Conference. “There’s a lot more opportunity, but also a lot more white noise.â€
Coats is referring to the pressure that cash-strapped biotechs are feeling to sell out and says he gets no less than five calls a day [...]
Posted in Events, Strategy Also tagged Eisai, HBA, Lonnel Coats, MGI Pharma, venture capital Leave a comment
Pfizer Adds FoldRx to its Specialty Care Unit